Incorporating pathologists' criteria of malignancy into the evolutionary model for cancer development

Journal of Cellular Biochemistry

Volumn 93, Issue 1, 2004, Pages 28-36

  Fischer, Andrew H ^a   Young, Kyle A ^b   DeLellis, Ronald A ^c  

^a University of Massachusetts   (United States)

^b SIMON FRASER UNIVERSITY   (Canada)

^c BROWN UNIVERSITY   (United States)

Author keywords

Carcinogenesis; Histopathology; Nuclear structure; Tissue

Indexed keywords

ARTICLE; CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CARCINOGENESIS; DISEASE COURSE; EVOLUTIONARY DEVELOPMENTAL BIOLOGY; HUMAN; PATHOLOGIST; PHENOTYPE; PRIORITY JOURNAL; TISSUE LEVEL; BIOLOGICAL MODEL; CELL TRANSFORMATION; GENETIC SELECTION; MUTATION; NEOPLASM; PATHOLOGY; REVIEW;

PYRONIA TITHONUS;

CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; PATHOLOGY, CLINICAL; PHENOTYPE; SELECTION (GENETICS);

EID: 16644401718     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20105     Document Type: Article

References (47)

1. Baserga R. 1965. The relationship of the cell cycle to tumor growth and control of cell division: A review. Cancer Res 25:581-595.
2. Basolo F, Pollina L, Fontanini G, Fiore L, Pacini F, Baldanzi A. 1997. Apoptosis and proliferation in thyroid carcinoma: Correlation with bcl-2 and p53 protein expression. Br J Cancer 75:537-541.
3. Bredel M. 2001. Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev 35:161-204.
4. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. 1999. Genetic instability and darwinian selection in tumours. Trends Cell Biol 9:M57-60.
5. Cairns J. 1975. Mutation selection and the natural history of cancer. Nature 255:197-200.
6. Conroy GC, Weber GW, Seidler H, Tobias PV, Kane A, Brunsden B. 1998. Endocranial capacity in an early hominid cranium from Sterkfontein, South Africa. Science 280:1730-1731.
7. Darwin C. 1859. The origin of species (1998). New York, New York: Random House, Inc. 104-105.
8. DeMay RM. 1996. The art and science of cytopathology. Chicago: American Society of Clinical Pathologists Press. Farid NR. 2001. P53 mutations in thyroid carcinoma: Tidings from an old foe. J Endocrinol Invest 24:536-545.
9. Fischer AH, Bond JA, Taysavang P, Battles OE, Wynford-Thomas D. 1998a. Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure. Am J Pathol 153:1443-1450.
10. Fischer AH, Chaddee DN, Wright JA, Gansler TS, Davie JR. 1998b. Ras-associated nuclear structural change appears functionally significant and independent of the mitotic signaling pathway. J Cell Biochem 70:130-140.
11. Fischer AH, Taysavang P, Weber C, Wilson K. 2001. Nuclear envelope organization in papillary thyroid carcinoma. Histol Histopathol 16:1-14.
12. Fischer AH, Taysavang P, Jhiang SM. 2003. Nuclear envelope regularity is induced by RET/PTC during interphase. Am J Pathol 163:1091-1100.
13. Fischer AH, Bardarov S, Jiang Z. 2004. Molecular aspects of diagnostic nucleolar and nuclear envelope changes in prostate cancer. J Cell Biochem 91:170-184.
14. Folkman J, Hahnfeldt P, Hlatky L. 2000. Cancer: Looking outside the genome. Nat Rev Mol Cell Biol 1:76-79.
15. Foulds L. 1954. The experimental study of tumor progression: A review. Cancer Res 14:327-339.
16. Fu YS, Regan JW, Richart RM. 1981. Definition of precursors. Gynecol Oncol 12:220-231.
17. Futuyma DJ. 1998. Evolutionary biology. Sunderland, Massachusetts: Sinauer Associates, Inc.
18. Gerlich D, Beaudouin J, Gebhard M, Ellenberg J, Eils R. 2001. Four-dimensional imaging and quantitative reconstruction to analyse complex spatiotemporal processes in live cells. Nat Cell Biol 3:852-855.
19. Grant PR. 1999. Ecology and evolution of Darwin's Finches. Princeton: Princeton University Press.
20. Hanahan D, Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70.
21. Ho GH, Galvano JE, Bisogna M, Borgen PI, Rosen PP, Tan LK, Van Zee KJ. 2000. In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology. Cancer 89:2153-2160.
22. Huang S, Ingber DE. 1999. The structural and mechanical complexity of cell-growth control. Nat Cell Biol 1:E131-E138.
23. Huang Y, De La Chapelle A, Pellegata NS. 2003. Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int J Cancer 104:735-744.
24. Kinzler KW, Vogelstein B. 1997. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 386:761-763.
25. Le Beau MM, Rowley JD. 1986. Chromosomal abnormalities in leukemia and lymphoma: clinical and biological significance. Adv Hum Genet 15:1-54.
26. Loeb LA. 1991. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 51:3075-3079.
27. Mendelsohn ML. 1960. The growth fraction: A new concept applied to tumors. Science 132:1496.
28. Mutter GL, Ince TA, Baak JP, Kust GA, Zhou XP, Eng C. 2001. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 61:4311-4314.
29. Nikiforov YE, Nikiforova M, Fagin JA. 1998. Prevalence of minisatellite and microsatellite instability in radiation-induced post-Chernobyl pediatric thyroid carcinomas. Oncogene 17:1983-1988.
30. Nowell PC. 1976. The clonal evolution of tumor cell populations. Science 194:23-28.
31. Pawelek JM. 2000. Tumour cell hybridization and metastasis revisited. Melanoma Res 10:507-514.
32. Petren K, Grant BR, Grant PR. 1999. A phylogeny of Darwin's Finches based on microsatellite DNA length variation. Proc Royal Soc London B 266:321-329.
33. Pettit SJ, Seymour K, O'Flaherty E, Kirby JA. 2000. Immune selection in neoplasia: Towards a microevolutionary model of cancer development. Br J Cancer 82:1900-1906.
34. Plass C. 2002. Cancer epigenomics. Hum Mol Genet 11:2479-2488.
35. Podos J. 2001. Correlated evolution of morphology and vocal signal structure in Darwin's Finches. Nature (London) [print] 409:185-188.
36. Roque L, Clode AL, Gomes P, Rosa-Santos J, Soares J, Castedo S. 1995. Cytogenetic findings in 31 papillary thyroid carcinomas. Genes Chromosomes Cancer 13:157-162.
37. Rosai J. 1996. Ackerman's surgical pathology. St. Louis, Missouri: Mosby-Year Book, Inc.
38. Sager R. 1982. The role of genomic rearrangements in tumor cell heterogeneity. In: Gordon M, editor. Tumor cell heterogeneity: Origins and implications. New York, New York: Academic Press, pp 411-423.
39. Shoemaker RH. 2000. Genetic and epigenetic factors in anticancer drug resistance. J Natl Cancer Inst 92:4-5.
40. Solovei I, Cavallo A, Schermelleh L, Jaunin F, Scasselati C, Cmarko D, Cremer C, Fakan S, Cremer T. 2002. Spatial preservation of nuclear chromatin architecture during three-dimensional fluorescence in situ hybridization (3D-FISH). Exp Cell Res 276:10-23.
41. Sreekantaiah C, Ladanyi M, Rodriguez E, Chaganti RS. 1994. Chromosomal aberrations in soft tissue tumors. Relevance to diagnosis, classification, and molecular mechanisms. Am J Pathol 144:1121-1134.
42. Susman RL. 1994. Fossil evidence for early hominid tool use. Science 265:1570-1573.
43. Tannock I. 1978. Cell kinetics and chemotherapy: A critical review. Cancer Treat Rep 62:1117-1133.
44. Tomlinson I, Bodmer W. 1999. Selection, the mutation rate and cancer: Ensuring that the tail does not wag the dog. Nat Med 5:11-12.
45. Tomlinson IPM, Novelli MR, Bodmer WF. 1996. The mutation rate and cancer. Proc Natl Acad Sci 93:14800-14803.
46. Tomlinson I, Sasieni P, Bodmer W. 2002. How many mutations in a cancer? Am J Pathol 160:755-758.
47. Wynford-Thomas D. 1993. Molecular basis of epithelial tumorigenesis: The thyroid model. Crit Rev Oncog 4:1-23.